Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.
Jiménez-Valerio G, Martínez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suárez C, García-Del-Muro X, Carles J, Viñals F, Graupera M, Indraccolo S, Casanovas O. Jiménez-Valerio G, et al. Among authors: carles j. Cell Rep. 2016 May 10;15(6):1134-43. doi: 10.1016/j.celrep.2016.04.015. Epub 2016 Apr 28. Cell Rep. 2016. PMID: 27134180 Free PMC article.
Molecular basis for the treatment of renal cell carcinoma.
Suárez C, Morales R, Muñoz E, Rodón J, Valverde CM, Carles J. Suárez C, et al. Among authors: carles j. Clin Transl Oncol. 2010 Jan;12(1):15-21. doi: 10.1007/s12094-010-0461-4. Clin Transl Oncol. 2010. PMID: 20080466 Review.
Emerging therapies for urothelial cancer.
Serrano C, Morales R, Suárez C, Núñez I, Valverde C, Rodón J, Humbert J, Padrós O, Carles J. Serrano C, et al. Among authors: carles j. Cancer Treat Rev. 2012 Jun;38(4):311-7. doi: 10.1016/j.ctrv.2011.10.007. Epub 2011 Nov 22. Cancer Treat Rev. 2012. PMID: 22113129 Review.
Role of immunotherapy in castration-resistant prostate cancer (CRPC).
Suárez C, Morales-Barrera R, Ramos V, Núñez I, Valverde C, Planas J, Morote J, Maldonado X, Carles J. Suárez C, et al. Among authors: carles j. BJU Int. 2014 Mar;113(3):367-75. doi: 10.1111/bju.12110. Epub 2013 Apr 12. BJU Int. 2014. PMID: 23650874 Review.
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C, Perez-Gracia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, Suarez C, Castellano D, del Alba AG, Lozano MD, Carles J, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Gurpide A, Lopez-Picazo JM, Hernandez AG, Mellado B, Martínez E, Moreno F, Font A, Calvo A. Prior C, et al. Among authors: carles j. PLoS One. 2014 Jan 24;9(1):e86263. doi: 10.1371/journal.pone.0086263. eCollection 2014. PLoS One. 2014. PMID: 24475095 Free PMC article.
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Bellmunt J, Suarez C, Gallardo E, Rodon J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J. Bellmunt J, et al. Among authors: carles j. Oncologist. 2014 Sep;19(9):917-8. doi: 10.1634/theoncologist.2014-0072. Epub 2014 Aug 20. Oncologist. 2014. PMID: 25142843 Free PMC article. Clinical Trial.
291 results